These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 26195515)

  • 21. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
    Cressey TR; Siriprakaisil O; Kubiak RW; Klinbuayaem V; Sukrakanchana PO; Quame-Amaglo J; Okochi H; Tawon Y; Cressey R; Baeten JM; Gandhi M; Drain PK
    Int J Infect Dis; 2020 Aug; 97():365-370. PubMed ID: 32553717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
    Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
    Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
    Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
    Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
    Custodio JM; Chuck SK; Chu H; Cao H; Ma G; Flaherty J; Ling J; Kearney BP
    Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
    Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
    Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
    Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
    Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
    Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
    PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
    Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
    Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
    J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
    Lambert-Niclot S; Allavena C; Grude M; Flandre P; Sayon S; Andre E; Wirden M; Rodallec A; Jovelin T; Katlama C; Calvez V; Raffi F; Marcelin AG
    J Antimicrob Chemother; 2016 Aug; 71(8):2248-51. PubMed ID: 27231280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
    Cirrincione LR; Podany AT; Havens JP; Bares SH; Dyavar SR; Gwon Y; Johnson TM; Amoura NJ; Fletcher CV; Scarsi KK
    J Antimicrob Chemother; 2020 May; 75(5):1242-1249. PubMed ID: 32065631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
    Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz R; Reirden D; Glenny C; Malhotra M; Anderson PL; Hosek S
    AIDS Res Hum Retroviruses; 2022 Nov; 38(11):840-846. PubMed ID: 35943868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.
    Foster R; McAllister J; Read TR; Pierce AB; Richardson R; McNulty A; Carr A
    Clin Infect Dis; 2015 Oct; 61(8):1336-41. PubMed ID: 26123937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.
    Cerrone M; Alfarisi O; Neary M; Marzinke MA; Parsons TL; Owen A; Maartens G; Pozniak A; Flexner C; Boffito M
    J Antimicrob Chemother; 2019 Jun; 74(6):1670-1678. PubMed ID: 30815689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
    Schauer AP; Sykes C; Cottrell ML; Prince H; Kashuba ADM
    J Pharm Biomed Anal; 2018 Feb; 149():40-45. PubMed ID: 29100029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.